Characterization and differentiation of equine experimental local and early systemic inflammation by expression responses of inflammation-related genes in peripheral blood leukocytes
- 858 Downloads
Local inflammation may progress into systemic inflammation. To increase our understanding of the basic immunological processes during transition of equine local inflammation into a systemic state, investigation into the equine systemic immune response to local inflammation is warranted. Therefore, the aim of this study was to investigate the innate peripheral blood leukocyte (PBL) immune response to local inflammation in horses, and to compare this response with the PBL immune response during the early phase of acute systemic inflammation. Expression of 22 selected inflammation-related genes was measured in whole blood leukocytes from 6 horses in an experimental cross-over model of lipopolysaccharide- (LPS-) induced acute synovitis (3 μg LPS intraarticularly; locally inflamed [LI] horses) and endotoxemia (1 μg LPS/kg intravenously; systemically inflamed [SI] horses). Multiple clinical and hematological/biochemical examinations were performed, and serial blood samples were analyzed by reverse transcription quantitative real-time PCR. Post-induction expression profiles of all genes were compared between study groups using principal component analysis (PCA) and hierarchical clustering.
Moderate synovitis and mild systemic inflammation of approximately 24 h duration was confirmed by clinical and paraclinical observations in LI and SI horses, respectively. In the LI group, samples obtained 3–16 h post-injection showed distinct clustering in the PCA compared with baseline levels, indicating a transcriptional response to local inflammation in PBLs in this time interval. There was no clinical or hematological indication of actual systemic inflammation. There was a clear separation of all LI samples from all SI samples in two distinct clusters, indicating that expression profiles in the two study groups were different, independent of time since LPS injection. Co-regulated genes formed four clusters across study groups which were distinctly differently regulated. Only few of individual genes displayed different expression between the study groups at all times after LPS injection.
Local inflammation in horses initiated an innate transcriptional response in PBLs, which differed from the transcriptional response during the early phase of systemic inflammation. This study may provide new insights into the immunobiology of PBLs during the transition of local inflammation into a systemic state.
KeywordsCytokines Endotoxemia Gene expression Horses Inflammatory transition Innate immunity Leukocytes Lipopolysaccharide Local inflammation Systemic inflammation
Acute inflammation denotes a series of generalized vascular and cellular events that is induced by the innate immune system in response to invading pathogens and tissue trauma [1, 2]. Systemic inflammation arises secondary to local inflammation if pro-inflammatory substances such as pathogen-associated molecular patterns (PAMPs), danger-associated molecular patterns (DAMPs), and perhaps pro-inflammatory cytokines are not successfully contained by local inflammatory processes, and if these pro-inflammatory substances overwhelm the initial systemic host defenses [1, 3, 4]. Activated peripheral blood leukocytes (PBLs), especially neutrophil granulocytes and monocytes, and endothelial cells are regarded key immunological cells in the initiation and progression of systemic inflammatory processes [5, 6].
In the equine clinic, systemic inflammation is a frequent sequela to diseases such as infectious colitis, metritis, peritonitis, pleuropneumonia, and intrauterine/neonatal infections . There is however not always a clear association between type of disease and the development of systemic inflammation; some horses suffering from local inflammation develop systemic inflammation while others apparently do not. The importance of closely monitoring patients at risk of developing systemic inflammation is widely recognized, as rapidly initiated targeted therapy is crucial to the treatment of systemic inflammatory conditions [7, 8]. However, diagnosing early acute systemic inflammation can be a challenge, as signs of disease during the transition of local inflammation into a systemic state inevitably will contain a mix of host responses to both local and systemic inflammatory processes. Also, local inflammation may initiate clinical and paraclinical signs which usually are thought of as evidence of systemic involvement, even though systemic inflammation does not appear to be present. This has been demonstrated in experimental studies of local inflammation in horses in which alterations in body temperature, whole blood white blood cell (WBC) count, and in some cases serum acute phase reactants (APRs), were present in response to LPS-induced synovitis [9, 10, 11, 12] and E. coli-induced endometritis . A systemic response like this might be due to release of locally produced pro-inflammatory cytokines to circulation, as cytokines are well known initiators of both fever , neutrophilia [15, 16], and acute phase responses . Another, more indirect, source of such cytokines might be PBLs and endothelial cells that are activated by pro-inflammatory substances released from locally inflamed tissues. From a clinical point of view, the most specific sign of the early acute stage of systemic inflammation regardless of cause seems to be the presence of pronounced neutropenia , indicating that activated neutrophils have marginated in the vasculature or have sequestrated in the perivascular tissue on a generalized level [19, 20].
In human medicine, research into systemic inflammation is focused on complementing clinical and standard paraclinical parameters with immunological markers to optimize future diagnosis and prognosis of systemic inflammatory conditions [21, 22]. In both human and equine research, the traditional way of investigating immune processes during the onset of systemic inflammation is by quantitating inflammatory mediators in serum or their corresponding gene expression in PBLs in response to experimentally induced systemic inflammation [23, 24, 25, 26, 27]. However, very little is known about the systemic immune response to local inflammation. To increase our understanding of basic immunological processes during transition of equine local inflammation into a systemic state, investigation of the PBL immune response to local inflammation is warranted. Such investigations might further indicate if specific PBL inflammatory mediators have a diagnostic potential in monitoring equine patients at risk of developing systemic inflammation.
Therefore, the aim of this study was to investigate the innate PBL immune response to local inflammation in horses, and to compare this response with the innate PBL immune response during the early phase of acute systemic inflammation. This was done by measuring the expression of 22 selected inflammation-related genes in whole blood leukocytes in an equine cross-over model of LPS-induced acute synovitis and endotoxemia. This study is part of a larger experiment investigating inflammatory processes during equine LPS-induced acute synovitis and endotoxemia. Clinical results and expression levels of single genes for the endotoxic horses have previously been presented in Vinther et al. .
Six healthy, adult (7.7 ± 5.4 years), Danish Warmblood or Danish Warmblood cross bred horses (2 geldings and 4 non-pregnant mares) with an initial body weight of 490 ± 39 kg were included in the study. The horses were owned by the University of Copenhagen. Prior to the experiment a full clinical examination and hematological and biochemical analyses of blood and radiocarpal synovial fluid were performed, and only horses without clinical or hematological/biochemical signs of acute or chronic inflammation  were included in the study. All horses were dewormed with ivermectin (Maximec®) and vaccinated against equine influenza and tetanus (ProteqFlu-Te®) prior to the study. Approximately 2 weeks before initiation of the study, horses were housed at the research station in individual 3 x 4 m box stalls, where they were fed an equine commercial grain mixture twice daily and had access to water and hay ad libitum.
A cross over study involving experimentally induced endotoxemia and lipopolysaccharide-(LPS) induced synovitis as models for systemic and localized inflammation, respectively, was performed. Horses were randomly assigned to start in one of the two study groups, and the experiments were performed simultaneously on one horse from each study group at a time. All horses had an acclimatization period in the climate controlled experimental facilities (maintained at a temperature of 12 ± 1 °C) of 5 days before initiation of the experiment. To eliminate possible effects of LPS tolerance there was a 4 week wash out period in between treatments . LPS was derived from Escherichia coli strain 055:B5 (#L2880, Sigma-Aldrich Denmark). Using a polyurethane jugular catheter (Milacath®, 14G, 150 mm), endotoxemia was induced over one minute with 1 μg/kg LPS diluted in isotonic saline (Baxter A/S, Denmark) to a total volume of 15 mL (systemically inflamed [SI] horses). Synovitis was induced in the left carpal joint by sterile intraarticular injection (Eickinject®, 21G, 40 mm) of 3 μg LPS diluted in 1 mL Ringer’s Acetate (Baxter A/S, Denmark) (locally inflamed [LI] horses). The LPS doses were established on the basis of the biological action of this particular batch of LPS in previous experiments, where the 3 ug per joint dose resulted in a clinically moderate but fully reversible synovitis that lasted for approximately 24 h, and the IV dose of 1 ug/kg resulted in a systemic inflammation with fully reversible clinical signs of inflammation that lasted for approximately 24 h. Due to intraarticular LPS injection failure in one LI horse, this group only consisted of 5 horses.
Examinations comprising general condition, rectal temperature (RT), heart rate (HR), respiratory rate (RR), mucosal membrane color, capillary refill time (CRT), and lameness score (LI horses only) were performed multiple times during the 24-h experimental period for both SI and LI horses (Additional file 1). Lameness was assessed independently by two observers using the AAEP lameness score . Two hours after intraarticular LPS injection the left carpal joint of the LI horses was evaluated for swelling and heat, and synovial fluid total protein and WBC were measured. 2.2 mL of synovial fluid was obtained by aseptic arthrocentesis (EDTA tubes, BD Company), and synovial fluid total protein and WBC was measured by use of a refractometer1 and a haemocytometer2, respectively. Additional arthrocenteses at post-injection hour (PIH) 4, 8, 16, and 24 were performed as part of a study without relevance for this experiment.
Dependent on specific requirements for analyses at each time point for sampling, 7.5–31.5 mL of blood was collected in syringes (Kruuse) through the indwelling jugular venous catheter and immediately transferred to the appropriate blood tubes. The first 5 mL of blood were drawn in a separate syringe and discarded. Baseline samples (PIH 0) were taken immediately before LPS injection. Blood for WBC and total neutrophil granulocyte and lymphocyte counts was collected in EDTA tubes (BD Company) at PIH 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. Blood for APRs was collected in serum tubes (serum amyloid A (SAA), haptoglobin, iron) or citrate tubes (fibrinogen) (BD Company) at PIH 0, 2, 4, 8, 16, and 24. SAA was measured by immunoturbidometry3. Haptoglobin was measured by a biochemical peroxidase assay in duplicate4. Iron was measured by colorimetric spectrophotometry5. Fibrinogen was measured by the Clauss method in an automated coagulometric analyzer6. A standardized volume of 2.5 mL of blood for RNA extraction was collected in PAXgene Blood RNA Tubes (Qiagen/BD Company), which allows for later recovery of total RNA from all cells presents in the blood sample. According to the manufacturer’s instruction PAXgene™ blood tubes were gently inverted 8–10 times after sampling and kept at room temperature for 2 to 24 h, before storage at -80 °C until RNA extraction. Samples from LI horses were collected at PIH 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24. For SI horses, genes of interest were previously found to be maximally differentially expressed within the first 8 h after LPS injection . Thus, only SI samples for PIH 1-8 were included in this study, serving as references for the expression profiles during acute systemic inflammation in these particular horses.
Relative gene expression in PBLs was measured by quantification of specific mRNA for the following 22 genes: IL1B, IL6, IL8, IL10, IL15, IL17, IL18, IL1RN, TNF, TLR4, CD14, ITGAM, ITGAX, SELL, MAPK14, CASP3, BCL2L1, MMP8, TIMP1, IL6ST, CCL5, and SOD2 (Additional file 2). As presented in Vinther et al. ; these 22 genes were significantly regulated in the SI horses at one or more time points during the first 8 h after intravenous LPS injection. Significant regulation was defined as a statistically significant change in gene expression of at least 2.5 fold compared with baseline levels.
Total RNA extraction and quality analysis, cDNA synthesis, specific primer design, pre-amplification and exonuclease treatment, and qPCR were performed as previously described . Briefly, total cellular RNA was extracted from PAXgene™ blood samples using PAXgene Blood miRNA Kits (Qiagen/BD Company) and treated with RNase-Free DNase sets (Qiagen/BD Company). Concentration and purity of total extracted RNA was determined by spectrophotometric analyses7. Samples containing less than 20 ng RNA/μL were evaporated (37 °C) to increase RNA concentration using a SPD111V SpeedVac Concentrator8. RNA integrity was estimated using an Agilent 2100 Bioanalyzer9 and RNA 6000 Nano Kits (Agilent Technologies). Each total RNA sample was assigned an RNA Integrity Number (RIN) from 1-10, with 10 being non-degraded RNA . Mean RIN value ± SD of all samples was 8.9 ± 0.9.
After extraction RNA was DNase treated a second time and 300 ng of total RNA per sample converted into first-strand cDNA by reverse transcription using a Tprofessional TRIO 3x4810 and QuantiTect Reverse Transcription Kits (Qiagen/BD Company) according to the manufacturer’s instructions. For assay validation, two separate cDNA replicates were performed for each RNA sample and a non-reverse transcriptase control was included. The cDNA samples were diluted (1:7.7) in low TE-buffer (VWR-Bie & Berntsen) and stored at -20 °C until pre-amplification procedures.
Gene specific primer pairs were designed as previously described  and synthesized at TAG Copenhagen (Denmark) or Sigma-Aldrich (Denmark). Transcript IDs, primer sequences, amplicon lengths, reaction efficiencies, and correlation coefficients are shown in Additional file 2. Primer amplification efficiencies, correlations and dynamic ranges were acquired from standard curves based on 4 separate dilution series (3 representing the whole sample material and 1 representing samples with high levels of IL6 to specifically meet the dynamic range of this particular gene) of pooled cDNA . Efficiencies between 0.91 and 1.12 and correlations above 0.97 were accepted.
Stocks of 200 nM primer pair mix in low TE-buffer (VWR-Bie & Berntsen, Denmark) were prepared combining equal amounts of all primers used in the study. Primer pair mix, TaqMan PreAmp Master Mix (Applied Biosystems), and cDNA were mixed and incubated at 95 °C for 10 min followed by 16 cycles of 95 °C for 15 s and 60 °C for 4 min. After pre-amplification cDNA was exonuclease treated. An aliquot of the pre-amplified cDNA was saved for preparation of dilution series, and finally cDNA was diluted in low TE-buffer before quantitative real-time PCR (qPCR).
Quantitative PCR was performed in 48.48 Dynamic Array Integrated Fluidic Circuits (IFC) on a BioMark Fluidigm thermocycler11 combining 48 samples with 48 primer sets in 2304 separate, simultaneous reactions . Each chip included a non-template control (NTC), a non-reverse transcriptase control, and cDNA dilution pools. Expression data (Cq values in heat maps) and melting curves were acquired using Fluidigm Real-Time PCR Analysis software 3.0.2 (Fluidigm). NTCs and melting curves were used to monitor for non-specific amplification or sample contaminations, and non-reverse transcriptase controls were used to assess potential DNA contamination. For both of these control samples, a minimum of 5 Cq-values between potential signals and a given sample signal were required, and only genes with a single melting peak (within 1 °C) were accepted for further data analyses.
Pre-processing and quantification of data
Expression data were exported to GenEx512 for pre-processing and quantification. Dilution pools were used as inter plate calibrators. Data was corrected for primer efficiencies for each primer assay individually. Using NormFinder  and GeNorm  the most stably expressed reference genes (ACTB, TBP, DIMT1, SDHA, HPRT1, and B2M) out of 7 putative candidates were selected for normalization. cDNA technical replicates were averaged. Finally, relative expression levels were established. For each gene of interest the expression level was set to 1 for the sample with the lowest level of expression. Expression levels for the specific gene of interest in all other samples irrespective of horse and time for sampling were then calculated relative to this sample during data transformation from Cq (log2) to relative quantities (relative fold change, linear scale).
Clinical and paraclinical data
Clinical and paraclinical data are presented as mean values except for lameness score, which is presented as a range of scores of individual horses. Selected clinical and paraclinical data are depicted graphically using SigmaPlot v. 12.5. Statistical analyses of selected clinical and hematological responses (RT, HR, RR, WBC counts, APRs) were analyzed with a two-way ANOVA random effect (mixed effect) model (R v. 3.1.2) where time and treatment (and their interaction) were fixed effects that influence the mean. A serial Gaussian correlation structure was included to allow for time-dependent correlation within each treatment on each horse and to allow for variation among horses. Distribution of data was evaluated by residual plots and data was log2-transformed to improve the model fits. The t-test was used to compare each time point with the baseline at PIH 0 and to compare time points between treatments groups (APRs only). The Bonferroni correction was used to account for testing multiple disease parameters, and statistical significance was defined as P < 0.0063 (significance level 0.05/8 parameters). No correction was made for testing at multiple time points as number of time point varied between parameters.
All analyses on expression data were performed on log2-transformed, autoscaled data using GenEx5. Data was autoscaled to have similar weights in the analyses regardless of magnitude and variation in expression levels of the 22 genes . To disclose multivariate responses in the study groups, the method of principal component analysis (PCA) was employed, grouping samples or genes based on gene co-expression patterns . In the present study, two PCAs were performed to visualize clusters of individual samples. The first PCA included expression data of all LI samples divided into the following subgroups: PIH 0, PIH 1-2, PIH 3-4, PIH 5-8, PIH 10-16, and PIH 20-24. The second PCA included expression data of SI (PIH 1-8) samples, LI (PIH 3-16) samples, and baseline samples for both study groups.
Based on expression level group means, differences in expression profiles of LI (PIH 3-16) samples in relation to SI (PIH 1-8) samples were further visualized in a heat map combining dendrograms of samples and genes. The dendrograms were performed by using agglomerative clustering, Euclidean distance as the distance measure and Ward’s method as clustering algorithm.
Clinical and paraclinical responses to endotoxin
At PIH 2, LI horses were 4 to 5° lame (5° scale), and had mild tachycardia and tachypnea (Fig. 1). There was swelling of the left carpal joint, palpable heat, and elevated synovial fluid total protein (35.2 ± 9.7 g/L) and WBC count (61.2 ± 31.6 x 109 cells/L) (reference values of non-inflamed synovial fluid total protein and WBC approximately 0.2 g/L and 87-167 x 106 cells/L, respectively ). During the following 2–6 h horses expressed varying degrees of depression, decreased appetite, mild colic, increased WBC counts, tachycardia, and tachypnea. Rectal temperature was slightly elevated at PIH 5-12. Lameness score was 4 to 5° at PIH 8. At PIH 24, horses were 1 to 3° lame and were bright, alert, and responsive. During the entire disease period all horses had a normal mucosal membrane color and CRT ≤ 2 s. None of the horses received analgesic treatment at any time during the study.
As seen in Fig. 2, serum SAA concentration for SI horses increased from 8 h post-injection until the end of the study whereas for LI horses SAA levels increased at 16 and 24 h of the onset of the study. Iron concentration was decreased after 16 h for both groups. In the LI group, haptoglobin and fibrinogen concentration was increased at PIH 24, while no significant changes were seen for these two acute phase proteins in the SI group. SAA concentration was different between SI and LI horses at PIH 8. Otherwise acute phase proteins did not differ between study groups within the 24-h observational period.
All horses in the SI and LI group developed classic signs of mild endotoxemia and moderate aseptic synovitis, respectively, and both clinical disease courses were self-limiting and lasted approximately for the expected 24 h. In addition to local inflammation and pain, LI-horses showed the systemic response of fever, increased peripheral blood WBC counts, and alterations in serum acute phase reactants previously described in other studies of equine induced local inflammation [9, 10, 11], clinically indicating the systemic presence of pro-inflammatory cytokines [14, 15, 16, 17]. A hallmark of acute systemic inflammation is the activation of the endothelium, leading to expression of adhesion molecules and leukocyte margination . This is clinically reflected by a rapidly initiated marked decrease in circulating leukocytes, which could be appreciated in the SI horses as early as one hour after induction of inflammation. In contrast, this hallmark of early systemic inflammation was not detected at any time point in the LI horses (Fig. 1). As all other vital clinical and hematological disease parameters, except for RR, in the LI horses only changed mildly, there is a strong indication that intraarticular LPS injection in these horses had not elicited secondary systemic inflammation.
Figure 3a reveals that samples LI (PIH 3-4) and LI (PIH 5-8) clustered distinctly from baseline samples, while LI (PIH 10-16) samples clustered with a partial overlap to baseline samples. This indicates changes in transcription of innate immune genes in circulating leukocytes approximately 3–16 h after intraarticular LPS injection. To our knowledge, this study is the first in horses to show that LPS-induced local inflammation can initiate a complex transcriptional response of innate immune genes in circulating leukocytes. As the horses by all appearances did not experience actual systemic inflammation, this further implies that the detection of transcription activity of innate inflammatory mediators in circulating leukocytes not necessarily equals a systemic inflammatory process in an individual. Whether the systemic response of fever, increased WBC count, and changes in serum APR concentration was due to the release of pro-inflammatory cytokines from the inflamed joint, or whether it was mediated by cytokines produces by activated PBLs, is unknown. However, the increase in WBC count and rectal temperature was not detectable until after the transcriptional onset of genes in PBLs, indicating a relationship between these signs of disease and activation of PBLs. In contrast to this, there was no PBL transcriptional response in LI horses at PIH 2, where horses were almost non-weight-bearing lame, had mild tachycardia and tachypnea, and had signs of acute joint inflammation such as local swelling and heat and elevated synovial fluid total protein and WBC count. This clinical presentation thus reflected a purely local inflammatory process where tachycardia and tachypnea may have been responses to pain from the inflamed joint . Our results thus suggest that elevated body temperature and an increased WBC count may be more indicative of the presence of innate inflammatory mediators in circulation than tachycardia and tachypnea. However, WBC was still significantly elevated at PIH 20 where the systemic expression response had abated.
The presence of inflammatory mediators in circulation in response to local inflammation has only been sparsely investigated in horses. In Cook et al. , increased serum levels of the lipid mediators prostaglandin E2 and thromboxane B2 were found after ischemia-induced local inflammation of the jejunum, and in a study by Campebell et al. , no difference in serum TNF-a concentration could be detected in LPS-induced synovitis despite significant changes in body temperature and circulating white blood cell composition in response to LPS. In induced endometritis in mares, transcription of the cytokines IL1B, IL6, IL8, IL10, TNF, and IL1RN were investigated in serial samples after inflammatory induction, but no differences were found when compared with pre-induction levels . In dogs, mild changes in WBC counts and in markers of coagulation (activated partial thromboplastin time, fibrinogen, protein-C, and -S) were seen in peripheral blood in response to experimentally induced localized soft tissue inflammation . Increased levels of for example serum IL-6, IL-10, and HMGB-1 were reported in pigs and mice in more severe models of local inflammation such as multiple trauma [43, 44] and acute kidney injury . Even though the exact mechanisms determining whether local inflammation is strictly contained, mediates a systemic response, or initiates actual systemic inflammation are unknown, the severity of the initial insult is probably an important factor. A general dose dependency of the in vivo response to LPS has previously been shown in an experimental study in cattle . Furthermore, a study on equine LPS-induced synovitis by Palmer and Bertone  specifically supports a dose dependency in the transition of local inflammation to a systemic state, as signs of systemic involvement (fever, altered leukocyte differential count) were only observed after high intraarticular injection doses of LPS. Factors such as pathogen virulence [47, 48] and immune competence of the host [49, 50] most likely contribute to determine the outcome of local inflammation.
In the present study, the PBL transcriptional response to local inflammation at PIH 3-16 was compared with the PBL transcriptional response during the early phase of acute systemic inflammation. The clear separation of all LI samples from all SI samples (Fig. 3b) indicates that expression profiles in the two study groups were substantially different independent of time since LPS injection. In this study, expression profiles of innate immune genes in circulating leukocytes could thus differentiate horses with systemic inflammation from horses with local inflammation and a secondary systemic transcriptional response, during both onset and progression of inflammation. For comparison, pronounced leukopenia, which is pathognomonic for systemic inflammation, was only seen in SI horses for approximately 4 h (Fig. 1). Like WBC, the APRs SAA, haptoglobin, fibrinogen, and iron are also widely used in the diagnosis of inflammation in both veterinary and human medicine [17, 51, 52, 53]. While transcription of leukocyte genes in the present study could be detected within the first few hours after LPS injection in both study groups, the acute phase reactants did not significantly change until PIH 8 at the earliest. A delay in acute phase responses compared with cytokine responses is not surprising as cytokines are well known mediators of APRs . It was however remarkable that the 24-h acute phase responses were similar between SI and LI horses despite the two distinctly different gene expression profiles.
To further characterize differences in the PBL transcriptional responses in the two study groups, a heat map combining two dendrograms was constructed using mean expression values for horses for SI (PIH 1-8) and LI (PIH 3-16) samples (Fig. 4). Color intensities in the heat map suggest that the expression response for the SI group in general was more pronounced and with greater fluctuations than for the LI group. This may also be appreciated by the scattered cluster of individual SI samples and the much tighter cluster of individual LI samples in Fig. 3b. The clustering of study groups seen in Fig. 3b is supported by the upper dendrogram in Fig. 4, which furthermore suggests subgrouping of SI samples in PIH 1-3 and PIH 4-8. The subgrouping of SI samples indicates a marked change in the expression profile for SI horses as the disease course progressed, which was likely due to the transition from relative lymphocytosis to relative neutrophilia. The dependence of gene expression results upon the composition of the various types of white blood cells is supported by both equine  and human [55, 56] studies and is for the present experiment discussed in detail in Vinther et al. . The heat map suggests that especially IL6, IL17, and most of the genes in Cluster A contributed to subgrouping of the inflammatory response in the SI group.
The 22 genes included in the study clustered in four main groups based on their temporal expression patterns (Cluster A-D, Fig. 4). Grouping of the genes IL8, IL1RN, and IL1B (Cluster C) was also seen in a study by Prabhakar et al. , in which 16 different genes were clustered by similarities in time profiles during a 24-h course of human LPS-induced systemic inflammation. In the present study, genes within especially Cluster A and B tended to follow the same expression pattern in the SI group, which indicates that the panel of genes could probably be reduced within these clusters without affecting the overall clustering analyses. Assessed visually, only few of the specific genes displayed distinctly different expression levels between study groups, irrespective of time since LPS injection. Except for IL8, IL1RN, and IL1B which seemed to be consistently higher expressed in SI-horses, single gene expressions thus only discriminated LI samples from SI samples in certain time intervals. IL1RN has not previously been investigated in systemic inflammation in the horse, and while IL8 and IL1B seem to be differentially expressed in equine experimental systemic inflammation [25, 27, 58], the transcriptional response of these genes in equine septic patients is more unclear [54, 59, 60, 61].
By evaluating expression profiles across the 22 genes instead of expression levels of each gene one by one, a more detailed and comprehensive picture of the complex immunological states of the cells was obtained. Multivariate methods for analysis such as PCA and hierarchical clustering are not frequently used in studies of innate immune gene expressions in large animals even though the well described interactions of inflammatory mediators [23, 62] make it a biologically relevant approach. Theoretically, the optimal experimental model to study innate immune processes during the transition of local inflammation into a systemic state would be a model in which systemic inflammation was obtained by inducing local inflammation. To our knowledge, no such experimental model is however well characterized in the horse and we therefore used the traditional intra-articular LPS model as a model for a localized inflammation, even though this may not be the most frequent source of a systemic inflammation. Another limitation of the study includes the fact that the group of horses was quite different according to gender, age, and origin. Furthermore, the complete clinical history of the horses prior to the inclusion examinations was not known, leaving questions on possible endotoxin tolerance due to previous endotoxin related diseases. However, none of the experimental horses showed a decreased pyrogenic response or lack of illness behavior, which are considered clinical hallmarks of tolerance [30, 63]. Additionally, induced in vivo endotoxin tolerance in horses subsides within 2-3 weeks , meaning that the risk of endotoxin tolerance in the experimental horses was low. The 4 week wash out period between the two challenges reduced the risk of induction of endotoxin tolerance, and the cross over study minimized effects of the large individual variation known to characterize the innate immune response [55, 64, 65]. The clear clustering of genes described here therefore represent robust findings, despite the low number of experimental horses and their different backgrounds. In the present study, by restricting samples in the SI group to the first 8 h after LPS injection, this model of systemic inflammation was representative of the expression profiles during the onset and progression of early systemic inflammation. Since there is very little knowledge of the possible PBL response to local inflammation, samples from LI horses were included covering the complete course of disease from clinical onset to approximate recovery (PIH 1-24).
To our knowledge, this is the first study in horses that specifically assesses the PBL transcriptional response to local inflammation and describes it in the context of onset and early development of systemic inflammation. New insights into the molecular mechanisms involved in the transition of local inflammation into a systemic state is needed for future advances in the diagnostic opportunities of early systemic inflammation in horses. A recent study by Hooijberg et al.  highlights the need for this to supplement standard clinical and paraclinical parameters in the differentiation of equine local and systemic inflammation. The study retrospectively investigated the diagnostic efficacy and combined predictive capability of the myeloperoxidase index (MPXI), and plasma fibrinogen, iron, and SAA concentrations for the diagnosis of systemic inflammation, local inflammation, or non-inflammatory disease in hospitalized horses. Based on quantitative results of these markers, diagnostic guidelines could not be formulated by Hooijberg and colleagues. The group of systemically inflamed horses in the study did not specifically represent early systemic inflammation, but given the results of the APRs in the present study this might not have changed the conclusion. In the present study, an important finding with direct clinical implication is the fact that self-limiting, moderate, local inflammation of brief duration mediated transcription of inflammation-related genes in PBLs. This suggests that a substantial part of equine patients with local inflammatory conditions are exposed to inflammatory mediators on a systemic level, emphasizing the relevance of close monitoring of this patient group.
The results in this study showed that LPS-induced local inflammation in horses could initiate a transcriptional response of inflammation-related genes in circulating leukocytes, and that such a response not necessarily equals a systemic inflammatory process in the individual. The co-expression patterns of multiple genes differentiated horses with a systemic transcriptional response to local inflammation from horses with early systemic inflammation, independent of the progression of inflammatory states. Only few of the individual genes displayed distinctly different expression levels between study groups irrespective of time since LPS injection. This study may provide new insights into the immunobiology of PBLs during the transition of local inflammation into a systemic state and encourage further research in the subject.
APR, acute phase reactant; CRT, capillary refill time; DAMP, damage associated molecular patterns; HR, heart rate; LI, locally inflamed; LPS, lipopolysaccharide; PAMP, pathogen-associated molecular pattern; PCA, principal component analysis; PIH, post-induction hour; RIN, RNA integrity number; RR, respiratory rate; RT, rectal temperature; RT-qPCR, reverse transcription quantitative real-time polymerase chain reaction; SAA, serum amyloid A; SI, systemically inflamed; WBC, white blood cell.
Clinical Refractometer T2, Atago.
Marienfeld, Th. Geyer.
LZ test SAA, EIKEN Chemocal Co., Tokyo, Japan.
Phase Range Hp Assay, Tridelta Development Ltd., Kildare, Ireland.
ADVIA 1650, Siemens, Lyngby, Denmark.
ACL 9000, Instrumentation Laboratory, Barcelona, Spain.
NanoDrop ND-1000 spectrophotometer, Saveen and Werner AB, Limhamn, Sweden.
SPD111V SpeedVac Concentrator, Thermo Scientific, Slangerup, Denmark.
Agilent 2100 Bioanalyzer, Agilent Technologies, Naerum, Denmark.
Tprofessional TRIO 3x48, Fisher Scientific Denmark, Slangerup, Denmark
48.48 Dynamic Array Integrated Fluidic Circuits and BioMark Fluidigm thermocycler, Fluidigm, California, USA.
GenEx5, MultiD, Göteborg, Sweden.
The authors gratefully acknowledge laboratory technician Karin Tarp for exceptional help with RT-qPCR analysis, and Claus Thorn Ekstrøm for performing statistical analyses of clinical and paraclinical data.
The experimental and laboratory procedures for the study presented in this paper were funded by Hesteafgiftsfonden, Kongeriget Danmarks Hesteforsikring, Foreningen Kustos af 1881, and University of Copenhagen.
Availability of data and materials
Data and materials supporting the results of this article are available upon request. Transcript IDs, primer sequences, amplicon lengths, reaction efficiencies, and correlation coefficients for gene specific primer pairs are shown in Additional file 2.
AMLV conceived the study, designed and carried out experimental and laboratory procedures, performed the statistical analyses of expression data, and drafted the manuscript. PMHH and RB participated in the interpretation of analytical data and in drafting the manuscript. KS participated in designing and performing laboratory procedures and carried out data pre-processing. SMA participated in the design of the study and carried out experimental procedures. PHA conceived the study, participated in its design and coordination and in drafting the manuscript. All authors have revised the manuscript critically for important intellectual content and have read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent to publish
All experimental procedures were approved by the Danish Animal Experiments Inspectorate (2011/561 − 1996) and carried out in agreement with the Danish Animal Testing Act. As the horses were University owned no consent was required in accordance with the above mentioned approval.
- 6.Janeway Jr CA, Travers P, Walport M, Shlomchik MJ. Innate Immunity. In: Austin P, Lawrance E, editors. Immunobiology. 5th ed. New York City: New York Garland Publishing; 2001. p. 35–91.Google Scholar
- 7.MacKay RJ. Endotoxemia. In: Smith BP, editor. Large Animal Internal Medicine. 4th ed. St. Louis, Missouri: Mosby Elsevier; 2009. p. 711–23.Google Scholar
- 12.Hulten C, Gronlund U, Hirvonen J, Tulamo RM, Suominen MM, Marhaug G, Forsberg M. Dynamics in serum of the inflammatory markers serum amyloid A (SAA), haptoglobin, fibrinogen and alpha2-globulins during induced noninfectious arthritis in the horse. Equine Vet J. 2002;34(7):699–704.CrossRefPubMedGoogle Scholar
- 13.Christoffersen M, Baagoe CD, Jacobsen S, Bojesen AM, Petersen MR, Lehn-Jensen H. Evaluation of the systemic acute phase response and endometrial gene expression of serum amyloid A and pro- and anti-inflammatory cytokines in mares with experimentally induced endometritis. Vet Immunol Immunopathol. 2010;138(1-2):95–105.CrossRefPubMedGoogle Scholar
- 18.Lohmann KL, Barton MH. Endotoxemia. In: Reed SM, Bayly WM, Sellom DC, editors. Equine Internal Medicine. 3rd ed. St. Louis, Missouri: Saunders Elsevier; 2010. p. 807–23.Google Scholar
- 20.Stockham SL, Scott MA. Fundamentals of veterinary clinical pathology. 2nd ed. Chichester: John Wiley and Sons Ltd; 2010.Google Scholar
- 26.Fossum C, Hjertner B, Olofsson KM, Lindberg R, Ahooghalandari P, Camargo MM, Brojer J, Edner A, Nostell K. Expression of tlr4, md2 and cd14 in equine blood leukocytes during endotoxin infusion and in intestinal tissues from healthy horses. Vet Immunol Immunopathol. 2012;150(3-4):141–8.CrossRefPubMedGoogle Scholar
- 29.Aiello SEE. The Merck veterinary manual. 8th ed. Whitehouse Station: Merck & Co., Inc; 1998.Google Scholar
- 31.Anonymous. Definition and classification of lameness. In: Guide for Veterinary Service and Judging of Equestrian Events. 4th ed. Lexington: American Association of Equine Practitioners; 1991. p. 19.Google Scholar
- 34.Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245–50.CrossRefPubMedGoogle Scholar
- 38.McIlwraith CW. Diagnosis of joint disease. In: Stashak TS, editor. Adam’s lameness in horses. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2002. p. 479–88.Google Scholar
- 52.Jacobsen S, Andersen PH. The acute phase protein serum amyloid A (SAA) as a marker of inflammation in horses. Equine Veterinary Education. 2007;19:36–46.Google Scholar
- 63.Krumrych W, Dabrowska J, Danek J, Soszynski D. Endotoxin tolerance in horses - clinical observations. Bull Vet Inst Pulawy. 1998;42(2):143–50.Google Scholar
- 65.Gruden K, Hren M, Herman A, Blejec A, Albrecht T, Selbig J, Bauer C, Schuchardt J, Or-Guil M, Zupancic K et al. A “crossomics” study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One. 2012;7(1):e28761.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.